Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging

Javadi, Sanaz; Ganeshan, Dhakshina Moorthy; Qayyum, Aliya; Iyer, Revathy B.; Bhosale, Priya

doi:10.2214/ajr.15.15199

Cited by 156 publications

(150 citation statements)

References 86 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…The current first-line treatment strategy for EOC is intensive surgical cytoreduction, followed by systemic chemotherapy with a platinum- or taxane-based regimen (17). However, advanced EOC [International Federation of Gynecological Oncology stages III–IV (18)] accounts for ~75% of total patients diagnosed with ovarian cancer with low (5-year) survival rates and a high recurrence rate of ~80% with failure to respond to conventional chemotherapy (19). Thus, it is necessary to develop novel chemotherapeutic approaches to increase the susceptibility of EOC to novel treatments, in order to improve the median progression-free survival and overall survival times.…”

Section: Introductionmentioning

confidence: 99%

Inhibitory effects of delphinidin on the proliferation of ovarian cancer cells via PI3K/AKT and ERK 1/2 MAPK signal transduction

Lim

Song

2017

Oncology Letters

View full text Add to dashboard Cite

Delphinidin is a member of the anthocyanidin family and is a natural pigment in red cabbage, berries, sweet potatoes and grapes. It possesses nutraceutical properties against various chronic diseases and types of cancer. However, little is known about its preventative effects on epithelial ovarian cancer, a disease that is associated with a low survival rate, a poor prognosis and a high rate of recurrence. The results of the present study demonstrated that the proliferation of SKOV3 cells decreased in a dose-dependent manner in response to treatment with delphinidin, and the phosphorylation of carcinogenic protein kinases associated with the progression of epithelial ovarian cancer was affected by delphinidin treatment. The levels of phosphorylated protein kinase B (AKT), ribosomal protein S6 kinase β-1 (P70S6K), ribosomal protein S (S6), extracellular signal-regulated kinase (ERK)1/2 and p38 were suppressed by increasing concentrations of delphinidin. Furthermore, the combination of certain pharmacological inhibitors, including phosphoinositide 3-kinase (PI3K; LY294002), ERK1/2 (U0126) and delphinidin significantly reduced the proliferation of SKOV3 cells and the phosphorylation of each of those target proteins. In addition, delphinidin treatment exerted anti-proliferative effects on paclitaxel-resistant SKOV3 cells, compared with treatment with paclitaxel alone. These results indicate that delphinidin inhibits the proliferation of SKOV3 cells through inactivation of PI3K/AKT and ERK1/2 mitogen-activated protein kinase signaling cascades, and that this cell signaling pathway may be a pivotal therapeutic target for the prevention of epithelial ovarian cancer, including paclitaxel-resistant ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibitory effects of delphinidin on the proliferation of ovarian cancer cells via PI3K/AKT and ERK 1/2 MAPK signal transduction

Lim

Song

2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Peritoneal fluid cytology was negative. Consequently, overall staging (according to revised FIGO criteria) [4] and grading was concluded as stage 1C1 (due to surgical aspiration) high-grade IT. After surgery, surveillance AFP levels returned to within the normal range within two months ( Fig.…”

Section: Presentation Of the Casementioning

confidence: 99%

Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management

Frazer

Hook

Addley

et al. 2019

Gynecologic Oncology

View full text Add to dashboard Cite

Immature teratomas (IT) are rare and recurrences uncommon. A 12-year-old female with grade 3 (high-grade) ovarian IT underwent surgical resection but experienced early recurrences; the first was treated with surgery but the second was metastatic and managed with chemotherapy, resulting in growing-teratoma-syndrome and need for further surgery. She now remains well in uneventful clinical follow-up. We believe chemotherapy could be reserved for very carefully selected recurrent IT cases, which may alter the natural history of disease.

show abstract

“…13,14 The detection of malignant ascites is an integral step in the clinical assessment of ovarian cancer. 15 Furthermore, malignant ascitic fluid is a major contributor to ovarian cancer progression and poor prognoses, 16 and is consequently closely monitored by oncologists. Many of these statistics arise from factors within the tumor microenvironment; therefore, it is critical to consider their role when striving to understand and devise treatment strategies to improve patient outcomes.…”

Section: -2877/2018/2(3)/031701/17mentioning

confidence: 99%

Review: Mechanotransduction in ovarian cancer: Shearing into the unknown

2018

View full text Add to dashboard Cite

Perspective: The role of mechanobiology in the etiology of brain metastasis APL Bioengineering 2, 031801 (2018) Ovarian cancer remains a deadly diagnosis with an 85% recurrence rate and a 5-year survival rate of only 46%. The poor outlook of this disease has improved little over the past 50 years owing to the lack of early detection, chemoresistance and the complex tumor microenvironment. Within the peritoneal cavity, the presence of ascites stimulates ovarian tumors with shear stresses. The stiff environment found within the tumor extracellular matrix and the peritoneal membrane are also implicated in the metastatic potential and epithelial to mesenchymal transition (EMT) of ovarian cancer. Though these mechanical cues remain highly relevant to the understanding and treatment of ovarian cancers, our current knowledge of their biological processes and their clinical relevance is deeply lacking. Seminal studies on ovarian cancer mechanotransduction have demonstrated close ties between mechanotransduction and ovarian cancer chemoresistance, EMT, enhanced cancer stem cell populations, and metastasis. This review summarizes our current understanding of ovarian cancer mechanotransduction and the gaps in knowledge that exist. Future investigations on ovarian cancer mechanotransduction will greatly improve clinical outcomes via systematic studies that determine shear stress magnitude and its influence on ovarian cancer progression, metastasis, and treatment.

show abstract

Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging

Abstract: We review the epidemiology of ovarian cancer, the new FIGO staging system, and the role of imaging in the assessment, staging, and follow-up of ovarian cancer.

Cited by 156 publications

References 86 publications

Inhibitory effects of delphinidin on the proliferation of ovarian cancer cells via PI3K/AKT and ERK 1/2 MAPK signal transduction

Inhibitory effects of delphinidin on the proliferation of ovarian cancer cells via PI3K/AKT and ERK 1/2 MAPK signal transduction

Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management

Review: Mechanotransduction in ovarian cancer: Shearing into the unknown

Contact Info

Product

Resources

About